[go: up one dir, main page]

NO20010531L - Medisinske aerosolformuleringer - Google Patents

Medisinske aerosolformuleringer

Info

Publication number
NO20010531L
NO20010531L NO20010531A NO20010531A NO20010531L NO 20010531 L NO20010531 L NO 20010531L NO 20010531 A NO20010531 A NO 20010531A NO 20010531 A NO20010531 A NO 20010531A NO 20010531 L NO20010531 L NO 20010531L
Authority
NO
Norway
Prior art keywords
aerosol formulations
moisture
active
compounds
medical aerosol
Prior art date
Application number
NO20010531A
Other languages
English (en)
Other versions
NO20010531D0 (no
NO328096B1 (no
Inventor
Manfred Keller
Kurt Herzog
Rudi Mueller-Walz
Holger Kraus
Original Assignee
Jago Res Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jago Res Ag filed Critical Jago Res Ag
Publication of NO20010531D0 publication Critical patent/NO20010531D0/no
Publication of NO20010531L publication Critical patent/NO20010531L/no
Publication of NO328096B1 publication Critical patent/NO328096B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Anvendelse av faste, farmasøytisk akseptable salter av kromoglysinsyre og/eller nedokromil som bærere i en terapeutisk og profylaktisk ikke-effektiv mengde i suspensjonsaerosolformuleringer av farmasøytisk aktive forbindelser som forbedrer dispergeringsegenskapene, øker den kjemiske og fysiske stabiliteten for fuktighets-sensitive aktive forbindelser, gjør det mulig med en mer nøyaktig dosering, særlig også for forbindelser aktive ved lav dose, og som som regel tillater utelatelsen av overflateaktive midler.
NO20010531A 1998-08-04 2001-01-31 Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil NO328096B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH163398 1998-08-04
PCT/CH1999/000360 WO2000007567A1 (de) 1998-08-04 1999-08-02 Medizinische aerosolformulierungen

Publications (3)

Publication Number Publication Date
NO20010531D0 NO20010531D0 (no) 2001-01-31
NO20010531L true NO20010531L (no) 2001-01-31
NO328096B1 NO328096B1 (no) 2009-12-07

Family

ID=4215022

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20010531A NO328096B1 (no) 1998-08-04 2001-01-31 Medisinske aerosolformuleringer samt ny anvendelse av kromoglysinsyre og/eller nedokromil
NO2012019C NO2012019I2 (no) 1998-08-04 2012-12-10 Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2012019C NO2012019I2 (no) 1998-08-04 2012-12-10 Kombinasjon av flutikason og formoterol, eller hvilket som helst farmasøytisk akseptabelt salt ellerderivat derav som er beskyttet ved basispatentet, inkludert kombinasjonen av flutikasonpropionat og formoterolfumarat

Country Status (19)

Country Link
US (1) US6475467B1 (no)
EP (1) EP1102579B1 (no)
JP (1) JP4672143B2 (no)
CN (1) CN1150890C (no)
AT (1) ATE234604T1 (no)
AU (1) AU749697B2 (no)
BE (1) BE2013C027I2 (no)
CA (1) CA2338680C (no)
CY (1) CY2012033I1 (no)
DE (1) DE59904648D1 (no)
DK (1) DK1102579T3 (no)
ES (1) ES2193726T3 (no)
FR (1) FR13C0057I2 (no)
LU (1) LU92254I2 (no)
NO (2) NO328096B1 (no)
NZ (1) NZ509489A (no)
PT (1) PT1102579E (no)
WO (1) WO2000007567A1 (no)
ZA (1) ZA200100569B (no)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
PE20010720A1 (es) * 1999-12-11 2001-07-26 Glaxo Group Ltd Distribuidor de medicamento
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
IL155335A0 (en) * 2000-10-12 2003-11-23 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
WO2002036591A2 (de) * 2000-10-31 2002-05-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative lösungsformulierung mit einem tiotropiumsalz
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10111843A1 (de) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von inflammatorischen Erkrankungen
DK1372608T3 (da) * 2001-03-30 2007-12-27 Jagotec Ag Medicinske aerosolformuleringer
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
HUE049426T2 (hu) * 2002-03-01 2020-09-28 Chiesi Farm Spa Szuperfinom formoterolkészítmény
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7311894B2 (en) * 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
KR20100055542A (ko) * 2002-06-25 2010-05-26 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
DK1671942T4 (da) * 2002-12-10 2014-09-22 Sunovion Pharmaceuticals Inc Aerosolformulering omfattende levalbuterol L-tartratsalt
EP1572217B1 (en) * 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
ME00420B (me) * 2003-03-20 2011-12-20 Boehringer Ingelheim Pharmaceuticals Inc Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani
WO2004103379A1 (en) * 2003-05-22 2004-12-02 Altana Pharma Ag Salmeterol and ciclesonide combination
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DK1658063T3 (da) * 2003-08-06 2014-05-12 Galephar M F Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
EP1699435A4 (en) * 2003-09-18 2009-05-20 Norton Healthcare Ltd PARTICLE
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
NZ548302A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
RU2440813C2 (ru) 2004-02-06 2012-01-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
RU2437658C2 (ru) * 2004-02-06 2011-12-27 Меда Фарма Гмбх Унд Ко.Кг Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20070185067A1 (en) * 2004-02-27 2007-08-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
CA2563556C (en) * 2004-04-20 2013-01-29 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
KR101725225B1 (ko) * 2004-04-23 2017-04-12 사이덱스 파마슈티칼스, 인크. 술포알킬 에테르 시클로덱스트린 함유 ｄｐｉ 제형
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ITRM20040268A1 (it) * 2004-05-31 2004-08-31 Italchimici S P A Formulazione farmaceutica di una soluzione stabile di formoterolo per via inalatoria e suo precedimento di preparazione.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
DK1809243T4 (da) * 2004-07-02 2022-09-05 Boehringer Ingelheim Int Aerosolsuspensionsformuleringer med tg 227 ea som drivmiddel
ATE520390T1 (de) 2004-12-27 2011-09-15 Beiersdorf Ag Glycopyrrolat in kosmetischen zubereitungen
DE102005029390A1 (de) * 2005-06-23 2007-01-04 Beiersdorf Ag Wirkstoffkombinationen aus Glycopyrroniumbromid und Polyolen
JP3955868B2 (ja) * 2004-12-27 2007-08-08 株式会社キングジム 書類等の綴じ具
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
JP2008538758A (ja) * 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
SI1881980T1 (sl) 2005-05-02 2012-12-31 Boehringer Ingelheim International Gmbh Nove kristalinične oblike tiotropijevega bromida
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
PT1971369E (pt) 2005-12-21 2009-10-20 Meda Pharma Gmbh & Co Kg Combinação de r,r-glicopirrolato, rolipram e budesonida para o tratamento de doenças inflamatórias
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP2010512182A (ja) * 2006-12-07 2010-04-22 イーライ リリー アンド カンパニー プラスグレルのための製品
DE102007002121B4 (de) * 2007-01-10 2008-12-11 Dräger, Karl-Heinz Verwendung eines Flüssiggasgemisches als nichtbrennbares Treibgas zum Feinstverteilen eines Reiz- oder Kampfstoffes
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
TR200907237A2 (tr) 2009-09-23 2011-04-21 B�Lg�� Mahmut Tiotropyum kuru toz kombinasyonu
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TR200907914A2 (tr) * 2009-10-20 2011-05-23 B�Lg�� Mahmut Kortlkosteroid içeren kuru toz formunda farmasötik bileşim.
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
CN102665678B (zh) * 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
RS53355B (sr) 2009-12-23 2014-10-31 Chiesi Farmaceutici S.P.A. Aerosolna formulacija za copd (hronične obstruktivne pulmonarne bolesti)
PE20121396A1 (es) * 2009-12-23 2012-10-24 Chiesi Farma Spa Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
TR200909793A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, mometazon ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909792A2 (tr) 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, kortikosteroid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909789A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Tiotropyum, budesonid ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu
TR200909791A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
TR200909790A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum, formoterol ve bir kromoglisik asit türevi kombinasyonu içeren kuru toz kombinasyonu.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
US20140113877A1 (en) 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
PH12013502546A1 (en) 2011-06-17 2014-01-27 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
JP6392242B2 (ja) 2012-12-17 2018-09-19 パリオン・サイエンシィズ・インコーポレーテッド 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
WO2014113638A1 (en) * 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
SI3089735T1 (sl) 2013-12-30 2018-10-30 Chiesi Farmaceutici S.P.A. Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol
CN106535889A (zh) * 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
CN106456595A (zh) 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于系统性病症的肥大细胞稳定剂治疗
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US11559505B2 (en) 2015-12-04 2023-01-24 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
AU2017328905C1 (en) 2016-09-19 2020-08-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
JP6781828B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
CA3037092C (en) * 2016-09-19 2022-06-21 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising glycopyrrolate and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
US10555903B2 (en) * 2016-10-14 2020-02-11 Glenmark Specialty S.A. Nebulizable compositions of tiotropium and formoterol
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
BR112022010188A2 (pt) 2019-12-02 2022-08-09 Chiesi Farm Spa Formulação farmacêutica de solução de aerossol, lata de aerossol, inaladores pressurizados de dose calibrada e uso da referida formulação
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
US20240238309A1 (en) * 2020-03-25 2024-07-18 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof
JP2025517808A (ja) * 2022-05-27 2025-06-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量噴霧吸入器のための医薬製剤
JP2025517809A (ja) * 2022-05-27 2025-06-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量噴霧吸入器のための医薬製剤
US20250302742A1 (en) * 2022-05-27 2025-10-02 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (no) 1956-03-21 1900-01-01
BE556587A (no) 1957-01-31 1957-04-11
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IL51314A (en) * 1976-01-30 1980-03-31 Fisons Ltd Disodium cromoglycate of low moisture content and pharmaceutical compositions containing it
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
CA1075854A (en) 1976-08-16 1980-04-22 Charles W. Simons Aerosol propellants for personal products
FR2390951A1 (fr) 1977-05-17 1978-12-15 Oreal Nouvelles compositions cosmetiques sous forme de laques aerosols pour fixer la chevelure
CY1333A (en) * 1980-04-30 1986-10-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS61158919A (ja) 1984-12-28 1986-07-18 Taisho Pharmaceut Co Ltd 水虫治療剤
GB8820398D0 (en) * 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
IE62780B1 (en) * 1988-09-10 1995-02-22 Fisons Plc Inhalation devices with a reduced risk of blockage
DE3839258A1 (de) * 1988-11-21 1990-05-23 Norbert Sass Verfahren zur herstellung eines suspensions-aerosols
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
US5753208A (en) * 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ES2159678T3 (es) * 1991-12-18 2001-10-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
SG42375A1 (en) 1991-12-31 2001-04-17 Solvay Medicinal aerosol formulation
SE523661C2 (sv) 1992-02-05 2004-05-04 American Pacific Corp Gas-vätskeblandning avsedd för användning som brandsläckningsmedel
US5301664A (en) 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9214765D0 (en) 1992-07-11 1992-08-26 Smithkline Beecham Plc Pressurised aerosol formulation
WO1994003056A1 (en) 1992-07-31 1994-02-17 Ian Alexander Edwin Maccormick Aerosol insecticide composition
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
CA2217950C (en) * 1995-04-14 2001-12-25 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
DE19616573C2 (de) * 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
FR2764899B1 (fr) 1997-06-19 2001-04-06 Boehringer Ingelheim Alimentai Nouveau melange propulseur et les preparations alimentaires en aerosol le contenant

Also Published As

Publication number Publication date
JP2002522374A (ja) 2002-07-23
AU4893999A (en) 2000-02-28
NO20010531D0 (no) 2001-01-31
CA2338680C (en) 2008-10-14
CN1150890C (zh) 2004-05-26
NO2012019I2 (no) 2014-06-02
LU92254I2 (fr) 2013-09-17
CY2012033I2 (el) 2015-08-05
AU749697B2 (en) 2002-07-04
FR13C0057I2 (fr) 2020-04-03
US6475467B1 (en) 2002-11-05
CN1315852A (zh) 2001-10-03
EP1102579B1 (de) 2003-03-19
WO2000007567A1 (de) 2000-02-17
ZA200100569B (en) 2001-09-26
CA2338680A1 (en) 2000-02-17
NO2012019I1 (no) 2012-12-27
DE59904648D1 (de) 2003-04-24
NO328096B1 (no) 2009-12-07
JP4672143B2 (ja) 2011-04-20
ATE234604T1 (de) 2003-04-15
FR13C0057I1 (no) 2013-11-15
EP1102579A1 (de) 2001-05-30
ES2193726T3 (es) 2003-11-01
BE2013C027I2 (no) 2018-12-04
CY2012033I1 (el) 2015-08-05
PT1102579E (pt) 2003-07-31
DK1102579T3 (da) 2003-07-14
NZ509489A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
NO20010531L (no) Medisinske aerosolformuleringer
CA2408142A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
BR0014320A (pt) Composições de substâncias terapêuticas solúveis em tocol
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
PT1027037E (pt) Composicao farmaceutica que compreende clodronato como ingredientes activo e celulose microcristalina silicificada como excipiente
PT96506A (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
NO20023875D0 (no) Stabilt nasalt, oralt eller sublingualt anvendbart preparat
WO2002030467A3 (en) Pharmaceutical composition containing honey for the treatment of wounds
BR9911598A (pt) Uso de derivados do ácido 2-hidróxi-4-trifluormetilbenzóico como inibidores da ativação do fator de transcrição nuclear nf-kb
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
BR0010150A (pt) Solução oral de prucalopride
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
ATE348621T1 (de) Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: FLUTIFORM / IFFERA (ALTERNATIVE NAVN FOR SAMME PRODUKT); NAT. REG. NO/DATE: 10-7474-10-7476 20120827; FIRST REG. NO/DATE: 21395-21397 20120710

Spc suppl protection certif: 2012019

Filing date: 20121210

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: FLUTIFORM / IFFERA (ALTERNATIVE NAVN FOR SAMME PRODUKT); NAT. REG. NO/DATE: 10-7474-10-7476 20120827; FIRST REG. NO/DATE: 21395-21397 20120710

Spc suppl protection certif: 2012019

Filing date: 20121210

Extension date: 20240802

MK1K Patent expired